Related Experiment Video
Updated: Aug 9, 2026

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells
Published on: February 21, 2014
The changes of estrogen receptor-beta variants expression in breast carcinogenesis: Decrease of estrogen
Byeong-Woo Park1, Ki-Suk Kim, Min-Kyu Heo
1Department of Surgery, Yonsei University College of Medicine, Seodaemun-ku, Seoul, Korea. bwpark@yumc.yonsei.ac.kr
Estrogen receptor-beta (ERbeta) variant expression changes during breast cancer development. ERbeta2 decreases while ERbeta5 increases in cancer tissues, particularly in postmenopausal patients, indicating distinct roles in cancer progression.
Area of Science:
- Endocrinology
- Molecular Biology
- Oncology
Background:
- Over five estrogen receptor-beta (ERbeta) variant forms exist, but their specific roles remain unclear.
- Investigating ERbeta variant expression is crucial for understanding breast cancer development.
Purpose of the Study:
- To investigate the expression levels of ERbeta variants in breast cancer tissues.
- To correlate ERbeta variant expression with clinicopathological parameters.
Main Methods:
- Quantitative analysis of ERbeta variant mRNA using reverse transcription polymerase chain reaction (RT-PCR) and triple primer PCR (TP-PCR).
- Comparison of ERbeta variant expression between 66 paired normal and cancer breast tissues.
- Statistical analysis of expression levels against clinicopathological factors.
Main Results:
- ERbeta2 and ERbeta5 constitute the majority of ERbeta expression in both normal and cancerous tissues.
- ERbeta and ERbeta2 expression significantly decreased in cancer tissues, especially in ERalpha-positive cancers.
- ERbeta5 expression significantly increased in cancer tissues, particularly in postmenopausal women, and correlated with favorable differentiation.
Conclusions:
- A decrease in ERbeta2 expression is a key factor in the reduced ERbeta levels observed in breast cancer.
- The altered expression of ERbeta variants, particularly ERbeta2 and ERbeta5, is associated with breast cancer development and progression.
- ERbeta5 upregulation in cancer tissues may indicate a favorable prognostic marker, especially in postmenopausal patients.
Related Concept Videos
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Mitogens and the Cell Cycle
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
